Send to:

Choose Destination

Links from Books

Use of left ventricular assist devices as destination therapy in end-stage congestive heart failure : a systematic review

Rector, Thomas S
Taylor, Brent C
Greer, Nancy L
Rutks, Indulis
Wilt, Timothy J
Quality Enhancement Research Initiative (US)
United States Department of Veterans Affairs Health Services Research and Development Service
Minneapolis VA Health Care System (US) VA Evidence Synthesis Program
Use of left ventricular assist devices as destination therapy in end-stage congestive heart failure : a systematic review [electronic resource] / prepared for Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service ; prepared by Evidence-based Synthesis Program (ESP) Center, Minneapolis VA Medical Center, Timothy J. Wilt ; investigators, principal investigators, Thomas S. Rector, Brent C. Taylor, research Associates, Nancy Greer, Indulis Rutks.
Evidence-based synthesis program
Country of Publication:
United States
[Washington, D.C.] : Dept. of Veterans Affairs, Health Services Research & Development Service, [2012]
1 online resource (1 PDF file (iii, 41 p.)) : ill.
Electronic Links:
Heart failure is defined as reduced ability of the heart to pump blood and maintain normal bodily function. Heart transplantation is currently the preferred treatment for end-stage heart failure but the supply of donor hearts is insufficient to meet the need and many patients are not eligible for transplantation due to age or comorbid conditions. Implantable mechanical pumps can assist the circulation of blood by the ventricles. Left ventricular assist devices (LVADs) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients awaiting transplant (a bridge to transplant) and as a last resort in patients with refractory heart failure who are not eligible for a heart transplant (destination therapy). In January 2010, the first newer generation, rotary continuous flow ventricular assist device (HeartMate II) was approved by the FDA for destination therapy. Eligibility criteria are essentially the same as those used to select patients for the pivotal clinical trial that included patients with shortness of breath and/or fatigue at rest or during minimal exertion despite treatment with optimal therapy for heart failure associated with a low ejection fraction (< 25%) who were not candidates for heart transplantation due to their age or co-morbid conditions. The purpose of this report is to review the scientific evidence for use of the current generation of left ventricular assist devices as destination therapy.
Clinical Trials as Topic
Heart Failure/therapy
Heart-Assist Devices*
Models, Theoretical
United States
Publication Type(s):
"May 2012."
Includes bibliographical references.
Description based on online resource; title from PDF title page (viewed on Oct. 16, 2012).
101592250 [Electronic Resource]

Supplemental Content

Loading ...
Support Center